Brokerage Firm Rating Update on Seattle Genetics (SGEN)

Seattle Genetics (SGEN) : Zacks Investment Research ranks Seattle Genetics (SGEN) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 10 research analysts is 2.1, which indicates as a Buy.

Seattle Genetics (SGEN) : 9 Wall Street analysts covering Seattle Genetics (SGEN) believe that the average level the stock could reach for the short term is $57.11. The maximum price target given is $130 and the minimum target for short term is around $38, hence the standard deviation is calculated at $28.59.


Company shares have received an average consensus rating of Hold for the current week Also, Equity Analysts at the Cantor Fitzgerald downgrades the rating on Seattle Genetics (NASDAQ:SGEN). The brokerage firm has issued a Hold rating on the shares. The shares were previously rated Buy. The rating by the firm was issued on July 27, 2016.

Seattle Genetics (NASDAQ:SGEN): The stock opened at $47 and touched an intraday high of $49.29 on Wednesday. During the day, the stock corrected to an intraday low of $46.925, however, the bulls stepped in and pushed the price higher to close in the green at $49.24 with a gain of 6.67% for the day. The total traded volume for the day was 1,077,643. The stock had closed at $46.16 in the previous trading session.

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Companys marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Companys pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics sugar-engineered antibody (SEA) technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.